Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (DE:1VT)
FRANKFURT:1VT
Total Valuation
Viking Therapeutics has a market cap or net worth of €3.40B. The enterprise value is €2.85B.
Market Cap€3.40B
Enterprise Value€2.85B
Share Statistics
Viking Therapeutics has 113,036,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,036,350
Owned by Insiders2.81%
Owned by Institutions0.42%
Financial Efficiency
Viking Therapeutics’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -17.12%.
Return on Equity (ROE)-0.12
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-17.12%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-2.44M
Employee Count45
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viking Therapeutics is ―. Viking Therapeutics’s PEG ratio is -3.63.
PE Ratio―
PS Ratio0.00
PB Ratio4.98
Price to Fair Value4.98
Price to FCF-49.98
Price to Operating Cash Flow-17.15
PEG Ratio-3.63
Income Statement
In the last 12 months, Viking Therapeutics had revenue of 0.00 and earned -109.96M in profits. Earnings per share was -1.01.
Revenue0.00
Gross Profit0.00
Operating Income-150.92M
Pretax Income-109.96M
Net Income-109.96M
EBITDA-150.57M
Earnings Per Share (EPS)-1.01
Cash Flow
In the last 12 months, operating cash flow was -224.58M and capital expenditures 0.00, giving a free cash flow of -224.58M billion.
Operating Cash Flow-224.58M
Free Cash Flow-224.58M
Free Cash Flow per Share-1.99
Dividends & Yields
Viking Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.09
52-Week Price Change-28.38%
50-Day Moving Average30.96
200-Day Moving Average26.14
Relative Strength Index (RSI)41.24
Average Volume (3m)384.00
Important Dates
Viking Therapeutics upcoming earnings date is Feb 11, 2026, After Close (Confirmed).
Last Earnings DateOct 22, 2025
Next Earnings DateFeb 11, 2026
Ex-Dividend Date―
Financial Position
Viking Therapeutics as a current ratio of 33.09, with Debt / Equity ratio of 0.11%
Current Ratio33.09
Quick Ratio33.09
Debt to Market Cap0.00
Net Debt to EBITDA0.23
Interest Coverage Ratio-1.61K
Taxes
In the past 12 months, Viking Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Viking Therapeutics EV to EBITDA ratio is -39.83, with an EV/FCF ratio of -49.69.
EV to Sales0.00
EV to EBITDA-39.83
EV to Free Cash Flow-49.69
EV to Operating Cash Flow-49.69
Balance Sheet
Viking Therapeutics has €714.57M in cash and marketable securities with €755.00K in debt, giving a net cash position of €713.82M billion.
Cash & Marketable Securities€714.57M
Total Debt€755.00K
Net Cash€713.82M
Net Cash Per Share€6.31
Tangible Book Value Per Share€8.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Viking Therapeutics is €82.85, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€82.85
Price Target Upside188.27% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast―